Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.54 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.53 |
| ▸ | YAP1 | P46937 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438827 | 1.00 | TNNI3K (0.54) | TNNI3KTEAD1YAP1MAPTCCR6 | |
| SCHEMBL24496003 | 0.85 | TEAD1 (0.50) | TNNI3KTEAD1YAP1MAPTBRAF | |
| SCHEMBL24496013 | 0.84 | TEAD1 (0.49) | TNNI3KTEAD1YAP1MAPTCCR6 | |
| SCHEMBL29648401 | 0.83 | TEAD1 (0.51) | TNNI3KTEAD1YAP1MAPTBRAF | |
| SCHEMBL24496260 | 0.83 | TEAD1 (0.51) | TNNI3KTEAD1YAP1MAPTBRAF | |
| SCHEMBL29438880 | 0.83 | TEAD1 (0.77) | TNNI3KTEAD1YAP1MAPTBRAF | |
| SCHEMBL22718190 | 0.83 | TEAD1 (0.77) | TNNI3KTEAD1YAP1MAPTBRAF | |
| SCHEMBL22843482 | 0.83 | CCR6 (0.43) | TNNI3KTEAD1YAP1MAPTCCR6 | |
| SCHEMBL24496005 | 0.83 | TNNI3K (0.51) | TNNI3KTEAD1YAP1MAPTCCR6 | |
| SCHEMBL29648405 | 0.83 | TNNI3K (0.51) | TNNI3KTEAD1YAP1MAPTCCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2022187518-A1 | SUBSTITUTED 4-PIPERIDINYL-IMIDAZO[4,5-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251048-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885TEAD1 4/4885YAP1 111/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885TEAD1 4/4885YAP1 111/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885TEAD1 4/4885YAP1 111/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885TEAD1 4/4885YAP1 111/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | TNNI3K 1435/4885TEAD1 7/4885YAP1 13/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885TEAD1 4/4885YAP1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.